Because 20–30% of HB tumours do not respond to the current chemotherapy consisting of cisplatin and adriamycin (Perilongo et al, 2000; Fuchs et al, 2002), and the great majority of HB tumours overexpresses IGF2, as shown in the present and earlier studies, HB may be the next target tumour for antibody therapy. This evidence concerns the gene IGF2 and neoplasm.